Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

This study is testing a new tablet drug called RSS0343 in people with non-cystic fibrosis bronchiectasis (NCFB) — a lung condition where the airways are permanently widened and scarred, causing repeated lung infections and mucus buildup. Researchers want to find out if the drug is safe and effective. **You may be eligible if...** - You are between 18 and 75 years old - Your CT scan shows bronchiectasis affecting one or more lobes of the lung, confirmed as NCFB - Your expected survival is more than 12 months - You are willing to use contraception if you could become pregnant **You may NOT be eligible if...** - Your main lung condition is pulmonary hypertension, COPD, or asthma (not bronchiectasis) - You currently have an active respiratory infection (COVID-19, flu, etc.) - You have psoriasis or lichen planus (skin conditions) - You weigh less than 45 kg (female) or 50 kg (male) Talk to your doctor to see if this trial is right for you.